From: Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity
 | VH | VL | |||
---|---|---|---|---|---|
scFv | V | D | J | V | J |
RCA7 | IGHV4-b*01 | IGHD2-8*02 | IGHJ4*02 | IGLV3-21*01 | IGLJ1*01 |
RCA9 | IGHV4-34*13 | IGHD2-8*02 | IGHJ4*02 | IGLV1-36*01 | IGLJ1*01 |
RCA11 | IGHV4-b*01 | IGHD2-8*02 | IGHJ4*02 | IGLV1-36*01 | IGLJ1*01 |
RCA15 | IGHV4-b*01 | IGHD2-8*02 | IGHJ4*02 | IGLV3-21*02 | IGLJ6*01 |
RCA34 | IGHV4-b*01 | IGHD2-8*02 | IGHJ4*02 | IGLV1-47*02 | IGLJ1*01 |
RCA37 | IGHV4-b*01 | IGHD1-7*01 | IGHJ5*02 | IGLV3-21*01 | IGLJ1*01 |
RCA47 | IGHV4-b*01 | IGHD2-8*02 | IGHJ4*02 | IGLV1-36*01 | IGLJ1*01 |
RCA48 | IGHV4-4*01 | IGHD1-7*01 | IGHJ5*02 | IGLV1-47*02 | IGLJ3*02 |
RCA13 | IGHV3-11*01 | IGHD3-22*01 | IGHJ4*02 | IGLV1-51*02 | IGLJ1*01 |
RCA30 | IGHV3-11*01 | IGHD3-22*01 | IGHJ4*02 | IGLV1-51*02 | IGLJ1*01 |